
Mar 7, 2025, 14:26
Myeloma Paper of the Day, March 7th, suggested by Robert Orlowski
Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Survival and proliferation of myeloma cells rely on splicing factor RBM39, and targeting RBM39 or MEK5 synergistically increases the cytotoxicity of bortezomib in myeloma cells via the inhibition of p65.”
Authors: Jia Liu et al.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 6, 2025, 05:06
Apr 6, 2025, 01:57
Apr 5, 2025, 20:21